Metabolic Syndrome in Childhood Cancer Survivors
- Determine the manifestations of metabolic syndrome (MS) in children and adolescents who
are survivors of childhood cancer (CCS).
- Compare the prevalence of MS in CCS to that of matched healthy siblings of similar age
- Evaluate insulin resistance (as measured by the euglycemic insulin clamp) in CCS and
compare to that of healthy siblings of similar age and gender.
- Assess the extent to which prevalent obesity and insulin resistance are correlated with
other factors that have been identified in the causal pathway associated with the
development of the MS that may be altered in the CCS ( e.g., growth-hormone secretion,
adipokines [adiponectin, leptin], inflammatory mediators [e.g., interleukin-6], tumor
necrosis factor-α, and C-reactive protein).
- Obtain dietary and physical activity assessments of CCS and healthy siblings.
- Explore demographic (age at treatment, sex-specific differences) and treatment-related
factors (exposures and dose-related associations with chemotherapeutic agents,
radiation, steroids) as potential correlates with insulin resistance, vascular
function, and MS in CCS.
OUTLINE: Patients undergo a comprehensive medical examination including current and past
medical history, family history, review of prescription medications, a physical examination
including a body and visceral-fat assessment, and anthropometric (DEXA and bone-age x-ray)
and blood pressure measurement. Blood samples are collected to measure growth hormone,
adipokines (adiponectin, leptin), cytokines (IL-6 and CRP), fasting insulin, fasting
glucose, lipids, oxidized LDL, hypothalami-pituitary-gonadal function (estrogen, FSH, LH,
testosterone), and thyroid function (free T4 and TSH). Patients also complete questionnaires
on dietary intake and physical activity.
Healthy siblings undergo a complete medical examination as patients do, including blood
samples collection and questionnaire administration.
Observational Model: Cohort, Time Perspective: Prospective
Metabolic syndrome (MS) in survivors of childhood cancer (CCS) vs controls
Day 1 and Day 2
Julia Steinberger, MD, MS
Masonic Cancer Center, University of Minnesota
United States: Institutional Review Board
|University of Minnesota Children's Hospital - Fairview||Minneapolis, Minnesota 55455|